key: cord-0909444-zv2q7kcu authors: Kho, Marcia M L; Reinders, Marlies E J; Baan, Carla C; van Baarle, Debbie; Bemelman, Frederike J; Diavatopoulos, Dimitri A; Gansevoort, Ron T; van der Klis, Fiona R M; Koopmans, Marion P G; Messchendorp, A Lianne; van der Molen, Renate G; Remmerswaal, Ester B M; Rots, Nynke; Vart, Priya; de Vries, Rory D; Hilbrands, Luuk B; Sanders, Jan-Stephan F title: The RECOVAC IR study: The Immune Response and safety of the mRNA-1273 COVID-19 vaccine in patients with chronic kidney disease, on dialysis, or living with a kidney transplant - A prospective, controlled, multicenter observational cohort by the REnal patients COVID-19 VACcination (RECOVAC) consortium date: 2021-05-26 journal: Nephrol Dial Transplant DOI: 10.1093/ndt/gfab186 sha: 17c95d0aa93b4fe2adfab81715594bd896fed982 doc_id: 909444 cord_uid: zv2q7kcu nan 3 COVID-19 is associated with severe morbidity and mortality in patients with chronic kidney disease (CKD), on dialysis and kidney transplant recipients [1, 2] . Although effective vaccination would lead to great clinical benefit, most studies with the presently available vaccines have excluded aforementioned patients. The resulting lack of data is a problem, because vaccine efficacy is known to be considerably lower in patients with CKD and renal replacement therapy [3] . Recent reports suggested that only a minority of kidney transplant recipients developed anti-SARS-CoV-2 antibodies after mRNA COVID-19 vaccination [4, 5] . The RECOVAC IR study (ClinicalTrials.gov NCT04741386) aims to assess immunogenicity and safety of COVID-19 vaccination in these specific patient groups up to 12 months post vaccination ( Figure 1 ). This prospective, controlled multicenter study includes 4 different cohorts: A: 175 patients with CKD stages 4/5 (eGFR <30 ml/min/1.73m 2 ), B: 175 on dialysis, C: 300 kidney transplant recipients and D: 200 controls (family or household members) in 4 university medical centers across the Netherlands. Included are people aged >18 years, without previously known COVID-19, active malignancy or immune deficiency (Supplementary data, Table S1 ). Participants receive two doses of the mRNA-1273 COVID-19 vaccine (®Moderna Biotech Spain, S.L.) with a 28-day interval. Primary endpoint is the SARS-CoV-2 spike S1-specific IgG antibody concentration on day 28 after second vaccination, measured by a validated fluorescent bead-based multipleximmunoassay [6] . Classification as responders or non-responders is based on seroconversion. The threshold for seropositivity based on Receiver Operator Curve (ROC) analysis is set at 1,04 AU/mL or 10,08 BAU/ml (binding antibody units) according to the recently adopted NIBSC/WHO COVID-19 reference serum 20/136, in individuals without measurable anti-S antibodies at baseline [7] . The percentages of responders in cohorts A, B, and C are compared to cohort D, as well as quantitative levels within and between cohorts to define groups that respond suboptimal to vaccination. Individuals who appear seropositive at baseline will be analyzed separately. 4 Secondary endpoints are antibody longevity up to one year post vaccination and SARS-CoV-2-specific T and B cell responses. Neutralizing capacity of SARS-CoV-2-specific antibodies are determined by a plaque reduction neutralization assay in a subgroup of participants, guided by S1-specific IgG level outcome [8] . SARS-CoV-2 specific T cell response are measured by an interferon (IFN)-ɣ release assay (IGRA) on freshly collected whole blood and IFN-ɣ ELISPOT on cryopreserved PBMC (Mabtech IFN-ɣ antibody pairs with alkaline phosphatase development). Results are expressed as IU IFN-ɣ per ml plasma (IGRA) or number of IFN-ɣ producing SARS-CoV-2 specific T-cells/million PBMC. Any spot above the medium control is considered positive. Number and phenotype of SARS-CoV-2 specific T cells will be studied by flowcytometry with HLAclass I tetramers as previously described [9, 10] . In-depth flowcytometric analyses for functional and phenotypical characterization of SARS-CoV-2 specific CD4 + and CD8 + T cell responses will be performed in a subset of patients by staining for typical phenotypic markers in combination with assessment of activation-induced markers (AIM) and cytokine production after specific stimulation with overlapping peptide pools from the complete SARS-CoV-2 protein divided over 2 subpools (S1 and S2) [11, 12] . SARS-CoV-2 specific B cells will be enumerated and phenotyped by flowcytometry as previously published [13] . SARS-CoV-2 specific memory B cells frequency will be determined by ELISPOT [14] . Infection with SARS-CoV-2 occurs via the mucosal surface of the respiratory tract. To understand if and how antibody concentrations in serum correlate with those on the mucosal surface [15] , nasal mucosal lining fluid is collected by non-invasive sampling (nasosorption) in a subset of patients. Induction, persistence and neutralizing capacity of mucosal antibodies against SARS-CoV-2 will be assessed and correlated to immune responses in the blood. Transplantation 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 Harmonization of methodology is crucial to enable the international scientific community to compare efficacy of different SARS-CoV-2 vaccines. We hope that our study design can serve as a reference and model for other studies in specific risk populations. To study the "correlate of protection" of kidney disease patients after COVID-19 vaccination, as reflected by SARS-CoV-2 infection incidence and severity, additional large population-based studies are needed. Such studies should disclose which immunological test provides the best surrogate for protection against the presently most abundant variant and different variants of SARS-CoV2. In conclusion, the results of the RECOVAC-IR study will reveal whether patients with CKD, on dialysis and kidney transplant recipients can be adequately protected against COVID-19 by vaccination, or whether other measures, like booster vaccinations, are required. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 Transplantation 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 10 Legend to Figure 1 : Four cohorts of study participants attend 5 study visits. At V1 and V2 participants receive the mRNA-1273 COVID-19 vaccine (Moderna). SARS-CoV-2 spike S1 antibodies are measured at all time points, including baseline. Primary endpoint is the antibody response at V3. Secondary endpoints are SARS-CoV-2 neutralizing antibodies and specific T and B cell responses, measured at V3-5 and SARS-CoV-2 specific nasal mucosal antibodies, measured at all time points. Safety is monitored by questionnaires to register solicited adverse events during 7 days after every vaccination. In immunized patients, anti-HLA antibodies are monitored after vaccination. SARS-CoV-2 infection incidence and disease outcome from first vaccination to end of study are exploratory endpoints. Transplantation 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 V1 T=0 V2 T=1 Transplantation 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 Factors associated with COVID-19-related death using OpenSAFELY COVID-19-related mortality in kidney transplant and dialysis patients: results of the ERACODA collaboration Vaccination in Chronic Kidney Disease Weak anti-SARS-CoV-2 antibody response after the first injection of an mRNA COVID-19 vaccine in kidney transplant recipients Impaired Humoral and Cellular Immunity after SARS-CoV2 BNT162b2 (Tozinameran) Prime-Boost Vaccination in Kidney Transplant Recipients SARS-CoV-2-Specific Antibody Detection for Seroepidemiology: A Multiplex Analysis Approach Accounting for Accurate Seroprevalence Persistence of antibodies to SARS-CoV-2 in relation to symptoms in a nationwide prospective study Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease Patients Expression of IL-7Ralpha and KLRG1 defines functionally distinct CD8(+) T-cell populations in humans Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability Producing Cells Before and After Transplantation Predicts Kidney Graft Rejection Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild versus severe COVID-19